Member Groups

The Alliance for Clinical Trials in Oncology seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.



The Australasian Lung Cancer Trials Group (ALTG) is Australia and New Zealand’s lung and thoracic cancer clinical research group. The ALTG is a multi-disciplinary organization dedicated to reducing the incidence, morbidity and mortality of lung and other thoracic cancers and improving the quality of life of these patients, carers and families in Australia and New Zealand through the coordination and facilitation of high quality clinical research. The ALTG collaborates with a number of organizations including the NHMRC Clinical Trials Centre (CTC) and Peter MacCallum Cancer Centre. Both of these groups are leaders in Australia for the design, conduct, analysis and publication of oncology clinical trials, including working with both Australia and international collaborative groups.



Associazioni per la RIcerca Clinica – Clinical Trials Promoting Group (APRIC-CTPG)



The British Thoracic Oncology Group (BTOG) is the multi-disciplinary group for professionals involved with thoracic malignancies in the UK and Ireland. BTOG aims to improve the care of patients with thoracic malignancies through multidisciplinary education, developing and advising on guidelines for patient care and facilitating and nurturing clinical trial ideas into full protocols. Telephone: 00 44 116 250 2811; Email:; Twitter: @BTOGORG



Cancer Trials Ireland co-ordinates, monitors and audits cancer trials in partnership with its network of 14 Cancer Trials Research Units in hospitals across Ireland. Established in 1996, more than 15,000 patients have participated in more than 350 Cancer Trials Ireland cancer trials. While the vast majority of trials adopted and sponsored by Cancer Trials Ireland are based in Ireland, in more recent times, a number of trials are now including international research centres. More than 95% of the island’s cancer treating consultants are members ensuring that research into cancer develops at a national level across all localities and across all types of cancer.



CECOG has been formed to unite centers of clinical oncology from Central- and Southeastern Europe as well as Israel into a body devoted to conducting clinical trials and providing postgraduate education in oncology. We, the Scientific Board and the members of CECOG, want to design and conduct controlled clinical trials in clinical oncology according to guidelines defined by Good Clinical Practice, perform these trials meticulously and analyze their results with the utmost scientific care. We strive to interact with the highest esteem for each other and with the overriding aim to improve the well-being and fate of patients.


The ECOG-ACRIN Cancer Research Group is a multidisciplinary, membership-based scientific organization that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. The Group is dedicated to its stated purpose, which is to achieve research advances in all aspects of cancer care and thereby reduce the burden of cancer and improve the quality of life and survival in patients with cancer.



The European Thoracic Oncology Platform (ETOP) is a not-for-profit organization promoting academic clinical research and the exchange of ideas in the field of thoracic oncology. It sponsors and manages an increasing number of translational research projects and clinical trials with an emphasis on advancing the knowledge in thoracic malignancies. ETOP comprises more than 50 collaborative groups and institutions from all over Europe and beyond.

The specific aims of ETOP are:

  • To serve as a meeting platform for European study groups and institutions engaged in research on thoracic malignancies
  • To foster intergroup studies among institutions and study groups across Europe and beyond
  • To sponsor and/or perform own studies and clinical trials
  • To foster scientific exchange on clinical and translational research among interested parties and beyond
  • To provide knowledge to partners in the field



The Spanish Lung Cancer Group (SLCG) was the first non-profit and independent research group, made up of oncologists, created in Spain with the aim of making advances in the treatment results of lung cancer. Since its foundation in 1991, The SLCG is focused in promoting and fostering translational research, thus enabling to rapidly incorporate the advances into the treatment of the disease and into daily clinical practice.

The SLCG consists of a wide variety of more than 360 specialists associated with lung cancer. It has a network of more than 150 hospitals spread throughout Spanish territory that conduct their research in a coordinated manner. More than 15500 lung cancer patients have been treated in the SLCG researches. Their results have been presented and published in national and international meetings and medical journals.


IFCT logo

IFCT is the French Cooperative Thoracic Intergroup. Created in 1999, IFCT is a non-profit organization strongly committed to conducting independent studies in lung cancer. Members include chest physicians, medical and radiations oncologists, thoracic surgeons, pathologists, and molecular biologists. IFCT projects are coordinated by a Clinical Research Unit accredited by the National Cancer Institute (INCa) and the National League Against Cancer. The association is managed by a Board of Directors made up of 13 elected members. A Scientific Committee is responsible for elaborating scientific projects. A technological platform enables experts to perform biobanking for translational research. The main goals of the association are:

  • To facilitate the development of clinical and translational research in Thoracic Oncology
  • To foster epidemiologic research and prevention studies
  • To provide continuing education for oncology professionals and share information on Thoracic Oncology;
  • To promote the evaluation of clinical practice in Thoracic Oncology.


JCOG logo-DarkBlue

The Japan Clinical Oncology Group (JCOG) is a multicenter clinical study group for cancer treatment fully funded by the national research grants in Japan. The goal of the JCOG is to establish effective standard treatments for various types of malignant tumors by conducting nationwide multicenter clinical trials, and to improve the quality and outcome of the management of cancer patients. JCOG consists of 16 subgroups and JCOG Lung Cancer Study Group (JCOG-LCSG) consists of 42 institutions, was established in 1982. JCOG-LCSG has been conducting many randomized trials for small cell lung cancer and elderly non-small cell lung cancer.


SWOG’s mission is to significantly improve lives through cancer clinical trials and translational research. Today, SWOG is a major part of the cancer research infrastructure in the United States and the world. SWOG has members in 47 states and six other countries as part of the NCI’s National Clinical Trials Network, or NCTN.


Trans Tasman Radiation Oncology Group Ltd – TROG Cancer Research has been improving the way in which radiotherapy is delivered to cancer patients for almost 30 years. The research our Australian and New Zealand-based members conduct is renowned internationally.

TROG’s research focus is on one type of treatment, radiotherapy, for the many types of cancers it can treat such as breast, lung, prostate, skin, head and neck. TROG Cancer Research is one of the largest clinical trials groups in Australia and works with its members, hospitals, universities and trial coordinating centres to sustain vital cancer research for our community.

Working with more than 70 cancer treatment centres in the Trans-Tasman, TROG has launched more than 100 trials with the help of 14,000 patients.